RxDoctor Payments Data

Jorge Rodriguez Mart, MD

Internal Medicine · Manati, PRNPI 1255494068

Payments from drug & device makers

$1,134in general payments, 2019–2025

Across 43 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$404
  • Johnson & Johnson$184
  • E.r. Squibb & Sons, L.L.C.$176
  • Abiomed$135
  • PBG Puerto Rico LLC$98
  • Dompe US, Inc.$27
  • plus $111 from 5 others

What the payments were for

  • Food & beverage$1,134100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca18$404
Johnson & Johnson6$184
E.r. Squibb & Sons, L.L.C.7$176
Abiomed1$135
PBG Puerto Rico LLC5$98
Dompe US, Inc.1$27
Dexcom, Inc.1$25
Novo Nordisk1$23
Chiesi USA, Inc.1$22
Amgen1$21
Merck1$20

How this compares

$1,134 in reported general payments places this provider in the 65th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,858
Medicare patients
25
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin250$285,309
FarxigaDapagliflozin Propanediol145$180,812
JanumetSitagliptin Phos/Metformin Hcl137$149,780
JentaduetoLinagliptin/Metformin Hcl101$90,756
EliquisApixaban75$90,454
XareltoRivaroxaban174$86,029
SynthroidLevothyroxine Sodium591$67,041
TradjentaLinagliptin58$59,170
JanuviaSitagliptin Phosphate41$57,322
Xigduo XrDapaglifloz Propaned/Metformin51$56,026
LantusInsulin Glargine,hum.Rec.Anlog198$38,620
KeppraLevetiracetam19$34,368
Ezetimibe1,062$26,855
Omega-3 Acid Ethyl Esters353$21,982
Trijardy XrEmpaglifloz/Linaglip/Metformin24$21,966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia, Janumet Xr$20$228,433193 claims
AstraZenecaFarxiga, Brilinta$404$196,365158 claims
Johnson & JohnsonXarelto$184$86,029174 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Manati

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →